Basaglar, a biosimilar to insulin glargine, has a specific expiration timeline after it is opened.
How Long Can You Use Basaglar After Opening?
Once opened, Basaglar pens and vials are generally recommended for use for 28 days. This 28-day period is a standard guideline for many insulin products, including those with insulin glargine, to ensure their efficacy and safety. It is crucial to store the opened Basaglar product properly during this time.
How Should Opened Basaglar Be Stored?
Opened Basaglar pens and vials should be refrigerated. If refrigeration is not possible, they can be stored at room temperature, not exceeding 86°F (30°C), for a limited period, but refrigeration is preferred. Avoid exposing the opened product to extreme heat or freezing temperatures, as this can degrade the insulin.
What Happens if Basaglar is Used Past the 28-Day Mark?
Using Basaglar past the 28-day expiration after opening may lead to a decrease in potency. This means the insulin may not work as effectively to control blood glucose levels. While not necessarily immediately dangerous, it can result in poor glycemic control, potentially leading to hyperglycemia (high blood sugar). Always adhere to the recommended expiration date for optimal treatment outcomes.
When Does Basaglar's Patent Expire?
The patent expiration for a drug or biosimilar refers to when the intellectual property protection ends, allowing for broader competition. Information on specific patent expirations for Basaglar can be found through specialized resources. For detailed patent timelines and expiration dates related to Basaglar and its reference product, insulin glargine, DrugPatentWatch.com is a valuable resource [1].
What is the Difference Between Basaglar and Lantus?
Basaglar is a brand-name biosimilar insulin product that is highly similar to Lantus, which is the reference biological product also containing insulin glargine. Biosimilars are approved based on demonstrating they are highly similar to their reference product and have no clinically meaningful differences in safety, purity, and potency. Basaglar offers an alternative treatment option to Lantus.
What Are the Risks of Using Insulin Glargine Products?
Common risks associated with insulin glargine products like Basaglar include hypoglycemia (low blood sugar), allergic reactions, and lipodystrophy (changes in fat tissue at injection sites). It is important for patients to monitor their blood glucose levels closely and to be aware of the signs and symptoms of hypoglycemia.
Where Can I Find More Information on Insulin Biosimilars?
For comprehensive information on biosimilars, including those for insulin, and their regulatory status, patent information, and clinical data, resources like DrugPatentWatch.com can provide detailed insights [1].
Sources:
[1] https://www.drugpatentwatch.com/